Endo Int'l (ENDP) Closes Par Pharma Acquisition; Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Outlook Therapeutics (OTLK) halted, news pending
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
RBC Capital Cuts Price Target on Endo Int'l (ENDP) Following Guidance Update
September 29, 2015 7:42 AM EDTRBC Capital maintained a Top Pick rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $100.00 (from $107.00), following a guidance update. ENDP pointed to a 3Q range of $720-740 million in revenue which is 4% below consensus at the midpoint.
Analyst... More
Guggenheim Reiterates Buy on Endo Int'l (ENDP) Following Updated Guidance
September 28, 2015 11:24 AM EDTGuggenheim reiterated a Buy rating and $110.00 price target on Endo International plc (NASDAQ: ENDP) following the company's updated financial guidance. Analyst Louise Chen continues to believe ENDP has set the stage for better-than-expected growth in '16+ driven by Xiaflex, Belbuca and the generics... More
